Drug intelligence / Profile preview

OC1 peptide

Development stage: Preclinical
Lead developer: Türkiye Sağlık Enstitüleri Başkanlığı
Modality: Peptides

Overview

OC1 peptide is a bioactive peptide derived from hazelnuts (Corylus avellana L.) that has demonstrated neuroprotective effects in in vitro models of Alzheimer's disease. It works by ameliorating cell viability, improving G2/M phase arrest, reversing late apoptosis, and reducing intracellular reactive oxygen species (ROS) formation in Aβ25-35 induced PC-12 cell lines. This peptide is being investigated as a potential neuroprotective agent for neurodegenerative diseases, including Alzheimer's disease.

Other names: Bioactive OC1 peptide (from hazelnut)

Beyond the preview

Go deeper on OC1 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC1 peptide.

Explore the full profile